Induction of IgA1 and IgA2 production in immature human fetal B cells and pre-B cells by vasoactive intestinal peptide.

Kimata H, Fujimoto M

Blood1 Apr 1995Cited by 27 (Europe PMC)

PMID7536491DOI10.1182/blood.v85.8.2098.bloodjournal8582098PepBankPUB-07536491

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study11

9 results from studies that gave the peptide. No result from this study comes from people.

01LabIn vitro (cells)Efficacy outcome
In human fetal B cells stimulated with anti-CD40 antibody, VIP induced IgA1 production.
In plain wordsIn lab tests on human fetal immune cells, VIP caused the cells to make IgA1 antibodies.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
IncreaseIgA1 production, fetal B cells
Study
humann: not reported in source
Human fetal B cells and bone marrow-derived pre-B cells stimulated with anti-CD40
Outcome group
Immune response · Immune and inflammation
Studied dose
Dose not stated
Source sentences
Summary
VIP induced IgA1, IgA2, and IgM production in sIgM+, CD19+ fetal B cells stimulated with anti-CD40 monoclonal antibody (MoAb)
1 context sentence(design, population, supporting numbers)
Summary · context
We studied the effects of vasoactive intestinal peptide (VIP) on IgA1 and IgA2 production in human fetal B cells and pre-B cells derived from bone marrow.
Report a problemFND-0753649101
02LabIn vitro (cells)Efficacy outcome
In human fetal B cells stimulated with anti-CD40 antibody, VIP induced IgA2 production.
In plain wordsIn lab tests on human fetal immune cells, VIP caused the cells to make IgA2 antibodies.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
IncreaseIgA2 production, fetal B cells
Study
humann: not reported in source
Human fetal B cells and bone marrow-derived pre-B cells stimulated with anti-CD40
Outcome group
Immune response · Immune and inflammation
Studied dose
Dose not stated
Source sentences
Summary
VIP induced IgA1, IgA2, and IgM production in sIgM+, CD19+ fetal B cells stimulated with anti-CD40 monoclonal antibody (MoAb)
1 context sentence(design, population, supporting numbers)
Summary · context
We studied the effects of vasoactive intestinal peptide (VIP) on IgA1 and IgA2 production in human fetal B cells and pre-B cells derived from bone marrow.
Report a problemFND-0753649102
03LabIn vitro (cells)Efficacy outcome
In human fetal B cells stimulated with anti-CD40 antibody, VIP induced IgM production.
In plain wordsIn lab tests on human fetal immune cells, VIP caused the cells to make IgM antibodies.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
IncreaseIgM production, fetal B cells
Study
humann: not reported in source
Human fetal B cells and bone marrow-derived pre-B cells stimulated with anti-CD40
Outcome group
Immune response · Immune and inflammation
Studied dose
Dose not stated
Source sentences
Summary
VIP induced IgA1, IgA2, and IgM production in sIgM+, CD19+ fetal B cells stimulated with anti-CD40 monoclonal antibody (MoAb)
1 context sentence(design, population, supporting numbers)
Summary · context
We studied the effects of vasoactive intestinal peptide (VIP) on IgA1 and IgA2 production in human fetal B cells and pre-B cells derived from bone marrow.
Report a problemFND-0753649103
04LabIn vitro (cells)Efficacy outcome
In human fetal B cells stimulated with anti-CD40 antibody, VIP did not induce production of IgG1, IgG2, IgG3 or IgG4.
In plain wordsIn lab tests on human fetal immune cells, VIP did not cause the cells to make IgG antibodies.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
No significant changeIgG1-IgG4 production, fetal B cells
Study
humann: not reported in source
Human fetal B cells and bone marrow-derived pre-B cells stimulated with anti-CD40
Outcome group
Immune response · Immune and inflammation
Studied dose
Dose not stated
Source sentences
Summary
without inducing the production of IgG1, IgG2, IgG3, IgG4, or IgE.
1 context sentence(design, population, supporting numbers)
Summary · context
We studied the effects of vasoactive intestinal peptide (VIP) on IgA1 and IgA2 production in human fetal B cells and pre-B cells derived from bone marrow.
Report a problemFND-0753649104
05LabIn vitro (cells)Efficacy outcome
In human fetal B cells stimulated with anti-CD40 antibody, VIP did not induce IgE production.
In plain wordsIn lab tests on human fetal immune cells, VIP did not cause the cells to make IgE antibodies.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
No significant changeIgE production, fetal B cells
Study
humann: not reported in source
Human fetal B cells and bone marrow-derived pre-B cells stimulated with anti-CD40
Outcome group
Immune response · Immune and inflammation
Studied dose
Dose not stated
Source sentences
Summary
without inducing the production of IgG1, IgG2, IgG3, IgG4, or IgE.
1 context sentence(design, population, supporting numbers)
Summary · context
We studied the effects of vasoactive intestinal peptide (VIP) on IgA1 and IgA2 production in human fetal B cells and pre-B cells derived from bone marrow.
Report a problemFND-0753649105
06LabIn vitro (cells)Efficacy outcome
In human pre-B cells treated with anti-CD40 antibody, VIP also induced IgA1 production.
In plain wordsIn lab tests on human immature immune cells, VIP caused the cells to make IgA1 antibodies.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
IncreaseIgA1 production, pre-B cells
Study
humann: not reported in source
Human fetal B cells and bone marrow-derived pre-B cells stimulated with anti-CD40
Outcome group
Immune response · Immune and inflammation
Studied dose
Dose not stated
Source sentences
Summary
The anti-CD40 MoAb plus VIP also induced IgA1, IgA2, and IgM production in sIgM-, CD19+ pre-B cells
1 context sentence(design, population, supporting numbers)
Summary · context
We studied the effects of vasoactive intestinal peptide (VIP) on IgA1 and IgA2 production in human fetal B cells and pre-B cells derived from bone marrow.
Report a problemFND-0753649106
07LabIn vitro (cells)Efficacy outcome
In human pre-B cells treated with anti-CD40 antibody, VIP also induced IgA2 production.
In plain wordsIn lab tests on human immature immune cells, VIP caused the cells to make IgA2 antibodies.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
IncreaseIgA2 production, pre-B cells
Study
humann: not reported in source
Human fetal B cells and bone marrow-derived pre-B cells stimulated with anti-CD40
Outcome group
Immune response · Immune and inflammation
Studied dose
Dose not stated
Source sentences
Summary
The anti-CD40 MoAb plus VIP also induced IgA1, IgA2, and IgM production in sIgM-, CD19+ pre-B cells
1 context sentence(design, population, supporting numbers)
Summary · context
We studied the effects of vasoactive intestinal peptide (VIP) on IgA1 and IgA2 production in human fetal B cells and pre-B cells derived from bone marrow.
Report a problemFND-0753649107
08LabIn vitro (cells)Efficacy outcome
In human pre-B cells treated with anti-CD40 antibody, VIP also induced IgM production.
In plain wordsIn lab tests on human immature immune cells, VIP caused the cells to make IgM antibodies.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
IncreaseIgM production, pre-B cells
Study
humann: not reported in source
Human fetal B cells and bone marrow-derived pre-B cells stimulated with anti-CD40
Outcome group
Immune response · Immune and inflammation
Studied dose
Dose not stated
Source sentences
Summary
The anti-CD40 MoAb plus VIP also induced IgA1, IgA2, and IgM production in sIgM-, CD19+ pre-B cells
1 context sentence(design, population, supporting numbers)
Summary · context
We studied the effects of vasoactive intestinal peptide (VIP) on IgA1 and IgA2 production in human fetal B cells and pre-B cells derived from bone marrow.
Report a problemFND-0753649108
09LabIn vitro (cells)Efficacy outcome
In human fetal B cells and pre-B cells, VIP induction of IgA was specific, because somatostatin or substance P with anti-CD40 antibody had no effect.
In plain wordsIn lab tests on human immune cells, VIP caused antibody production, but somatostatin and substance P did not.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
IncreaseSpecificity of VIP-induced IgA compared with other neuropeptides
Study
humann: not reported in source
Human fetal B cells and bone marrow-derived pre-B cells stimulated with anti-CD40
Comparator
Somatostatin or substance P
Outcome group
Immune response · Immune and inflammation
Studied dose
Dose not stated
Source sentences
Summary
This induction by VIP was specific, as the anti-CD40 MoAb plus other neuropeptides [ie, somatostatin (SOM) or substance P (SP)] had no effect
1 context sentence(design, population, supporting numbers)
Summary · context
We studied the effects of vasoactive intestinal peptide (VIP) on IgA1 and IgA2 production in human fetal B cells and pre-B cells derived from bone marrow.
Report a problemFND-0753649110

Studies that did not test the peptide alone2

In this study, Vasoactive intestinal peptide (VIP, aviptadil) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Vasoactive intestinal peptide (VIP, aviptadil).

10LabNot a test of Vasoactive intestinal peptide (VIP, aviptadil) aloneIn vitro (cells)Efficacy outcome
In human pre-B cells, immunoglobulin production induced by anti-CD40 antibody plus VIP was enhanced by the addition of interleukin-7.
In plain wordsIn lab tests on human immature immune cells, adding interleukin-7 to anti-CD40 and VIP increased antibody production further.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
IncreaseEnhancement of pre-B cell Ig production by IL-7
Study
humann: not reported in source
Human fetal B cells and bone marrow-derived pre-B cells stimulated with anti-CD40
Outcome group
Immune response · Immune and inflammation
Source sentences
Summary
which was enhanced by the addition of interleukin-7 (IL-7).
1 context sentence(design, population, supporting numbers)
Summary · context
We studied the effects of vasoactive intestinal peptide (VIP) on IgA1 and IgA2 production in human fetal B cells and pre-B cells derived from bone marrow.
In this study, Vasoactive intestinal peptide (VIP, aviptadil) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Vasoactive intestinal peptide (VIP, aviptadil).
Report a problemFND-0753649109
11LabNot a test of Vasoactive intestinal peptide (VIP, aviptadil) aloneIn vitro (cells)Efficacy outcome
In human fetal B cells and pre-B cells, a VIP antagonist specifically blocked the induction of IgA by VIP.
In plain wordsIn lab tests on human immune cells, a VIP blocker stopped the antibody production that VIP caused.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
Not applicableBlock of VIP-induced IgA production by a VIP antagonist
Study
humann: not reported in source
Human fetal B cells and bone marrow-derived pre-B cells stimulated with anti-CD40
Comparator
VIP antagonist
Outcome group
Immune response · Immune and inflammation
Source sentences
Summary
and moreover, the induction was specifically blocked by a VIP antagonist.
1 context sentence(design, population, supporting numbers)
Summary · context
We studied the effects of vasoactive intestinal peptide (VIP) on IgA1 and IgA2 production in human fetal B cells and pre-B cells derived from bone marrow.
In this study, Vasoactive intestinal peptide (VIP, aviptadil) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Vasoactive intestinal peptide (VIP, aviptadil).
Report a problemFND-0753649111

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 12:58 UTC
Study results updated
Version 1
9 Oct 2026, 12:41 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.